Money & Investing
Trendline
Otis Worldwide Corporation Stock Price Target Reduced to $85.09, Still Implies 12% Upside
Read More
Trendline
Standard Asset Company Launches $1.5 Billion Bitcoin and UAE Real Estate Strategy with Coinbase Asset Management
Read More
Trendline
CHICAGO TRUST Co NA Invests $3.09 Million in Newmont Corporation, Expanding Institutional Holdings
Read More
Trendline
Invesco Semiconductors ETF (PSI) Faces Volatility Amidst AI Demand and Market Risks
Read More
Trendline
CohnReznick Appoints David Unger as Tax Partner in Private Client Services
Read More
Trendline
Wall Street Zen Downgrades Rivian Automotive to 'Sell' Despite Recent Positive Earnings
Read More
Trendline
Tristan Thompson Warns Cryptocurrency Traders Against Treating Profits as 'Fairy-Tale Money'
Read More
Trendline
Kite Realty Group Raises Full-Year FFO and NOI Guidance Following Strong Q3 2026 Performance
Read More
Trendline
Superman Comic Book Collectibles Maintain High Value Amidst Evolving Market Trends
Read More
USA Today
Rich Americans now say they need $2.6M to retire. Are they hitting it?
Read More
Trendline
Sequoia Capital Entities Adjust Beneficial Ownership in Maplebear Inc. Common Stock
Read More
Trendline
Capital Group Dividend Value ETF (CGDV) Increases Holdings in Technology and Financial Sectors
Read More
Trendline
John Hancock Financial Opportunities Fund Reports Significant Decline in Short Interest for October
Read More
Trendline
Investment Strategists Advocate Blended Free Cash Flow Analysis for U.S. Stock Valuation
Read More
Trendline
Accounting Firms Offer Comprehensive Financial Services Including Auditing and Tax Preparation
Read More
Trendline
JPMorgan Raises Citigroup Price Target to $148.50, Maintains Overweight Rating
Read More
Trendline
Asante Gold Corporation Secures Waiver Extension for US$100 Million Funding Deadline
Read More
Rapid Read
Digital Estate Planning Becomes Crucial for Managing Post-Mortem Digital Assets
Read More
Trendline
UCSB Acquisition, a SPAC Led by Chinese Executives, Files for $60 Million U.S. IPO
Read More
Trendline
Acumen Pharmaceuticals Discontinues Alzheimer's Drug Development After Phase 2 Failure, Stock Plummets 80%
Read More